AR037304A1 - Composiciones liofilizadas de anticuerpos monoclonales - Google Patents
Composiciones liofilizadas de anticuerpos monoclonalesInfo
- Publication number
- AR037304A1 AR037304A1 ARP020104325A ARP020104325A AR037304A1 AR 037304 A1 AR037304 A1 AR 037304A1 AR P020104325 A ARP020104325 A AR P020104325A AR P020104325 A ARP020104325 A AR P020104325A AR 037304 A1 AR037304 A1 AR 037304A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibody
- liofilized
- compositions
- monoclonal antibodies
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composición farmacéutica sólida, mejorada, que comprende una composición de anticuerpo monoclonal, liofilizada, que muestra una estabilidad mejorada en su forma seca y una elevada temperatura de transición vítrea. Una composición de anticuerpo monoclonal, liofilizada, que comprende un anticuerpo monoclonal terapéuticamente activo, o un fragmento de dicho anticuerpo, en forma de una mezcla con un excipiente estabilizante que consiste en una combinación de un disacárido y un hidroxietil almidón. Es preferible que el anticuerpo monoclonal sea el abciximab.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34206301P | 2001-11-09 | 2001-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037304A1 true AR037304A1 (es) | 2004-11-03 |
Family
ID=23340162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104325A AR037304A1 (es) | 2001-11-09 | 2002-11-11 | Composiciones liofilizadas de anticuerpos monoclonales |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1455822A4 (es) |
JP (1) | JP2005508992A (es) |
AR (1) | AR037304A1 (es) |
CA (1) | CA2466641A1 (es) |
MX (1) | MXPA04004459A (es) |
TW (1) | TW200303213A (es) |
WO (1) | WO2003041637A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982080B2 (en) * | 2002-03-15 | 2006-01-03 | Wyeth | Hydroxyethyl starch—containing polypeptide compositions |
CA2744510A1 (en) * | 2008-12-09 | 2010-06-17 | F.Hoffmann-La Roche Ag | Method for obtaining an excipient-free antibody solution |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
LT3111954T (lt) | 2010-11-05 | 2019-07-10 | Novartis Ag | Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus |
BR112020004902A2 (pt) | 2017-09-15 | 2020-09-15 | Amgen Inc. | processo para formulação farmacêutica liofilizada de uma proteína terapêutica |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0229810B1 (en) * | 1985-07-09 | 1991-10-16 | Quadrant Bioresources Limited | Protection of proteins and the like |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
WO1993014191A1 (en) * | 1992-01-21 | 1993-07-22 | Cryopharm Corporation | Method of freezing cells and cell-like materials |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
IL122482A (en) * | 1995-06-07 | 1999-10-28 | Quadrant Holdings Cambridge | Methods for stably incorporating substances within dry foamed glass matrices and compositions obtained thereby |
US5762961A (en) * | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
EP2325205A3 (en) * | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
-
2002
- 2002-10-18 EP EP02773798A patent/EP1455822A4/en not_active Withdrawn
- 2002-10-18 CA CA002466641A patent/CA2466641A1/en not_active Abandoned
- 2002-10-18 JP JP2003543524A patent/JP2005508992A/ja active Pending
- 2002-10-18 MX MXPA04004459A patent/MXPA04004459A/es unknown
- 2002-10-18 WO PCT/US2002/033272 patent/WO2003041637A2/en not_active Application Discontinuation
- 2002-11-08 TW TW091133319A patent/TW200303213A/zh unknown
- 2002-11-11 AR ARP020104325A patent/AR037304A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2466641A1 (en) | 2003-05-22 |
TW200303213A (en) | 2003-09-01 |
EP1455822A2 (en) | 2004-09-15 |
EP1455822A4 (en) | 2004-12-29 |
MXPA04004459A (es) | 2005-05-16 |
WO2003041637A2 (en) | 2003-05-22 |
WO2003041637A3 (en) | 2004-01-22 |
JP2005508992A (ja) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607349A2 (pt) | combinação de xolair com agente imunossupressor | |
CL2007000664A1 (es) | Procedimiento para obtener una composicion termoestable de proteina seca y alcohol liquido anhidro premezclando la fraccion liquida anhidra, separadamente premezclar la fraccion seca y mezclar obteniendo una masa homogenea manteniendo la temperatura de la mezcla por debajo de la temperatura de endurecimiento de la composicion. | |
NO2017027I2 (no) | efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
UA89798C2 (ru) | Стабильный водный препарат антитела в гистидинацетатном буфере | |
UA116080C2 (uk) | Ліофілізована композиція терапевтичного пептидного антитіла | |
CL2007003771A1 (es) | Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an | |
ECSP045197A (es) | Preparación liofilizada que contiene un anticuerpo contra el receptor EGF | |
EA200800233A1 (ru) | Композиция иммуноконьюгата | |
BRPI0513327A (pt) | composição farmacêutica sólida ou lìquida compreendendo neurotoxina botulìnica | |
PE20081477A1 (es) | Formulacion liofilizada mab abeta | |
AR028979A1 (es) | Mutantes de alfa-amilasa con propiedades alteradas | |
CR10012A (es) | Formulaciones de proteina de fusión de Inmunoglobulina | |
CR20120384A (es) | Composición de farmaco conjugado | |
NO20052595D0 (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
BR0017013A (pt) | Composições de antibiótico azalìdeo | |
AR069860A1 (es) | Metodo para purificar un anticuerpo cd20 | |
DE60045464D1 (de) | Kraftstoffzusammensetzung mit hydrokarbyl-substituierten polyoxyalkylenaminen | |
WO2005058283A3 (en) | Stabilised compositions of factor vii polypeptides | |
WO2006037052A3 (en) | Modulating mxa expression | |
EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
EP1993601A4 (en) | NON-SPRAYED PROTECTION REGIONS OF PNEUMOKOKEN SURFACES PSPA AND PSPC | |
DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
AR037304A1 (es) | Composiciones liofilizadas de anticuerpos monoclonales | |
NO20034278D0 (no) | Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner | |
ATE362481T1 (de) | Lantibiotikum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |